Log in with your email address username.


[Correspondence] HIV treatment: time to lean forward

The Lancet (Oct 10, p 1420) stated that the new WHO antiretroviral therapy (ART) guidelines are based on trials that “showed promising, but modest, benefits for affected individuals, and for reducing HIV transmission following early treatment initiation”.1 The benefits are not modest. START showed a 57% reduction in adverse events, including AIDS, for individuals who started ART immediately,2 TEMPRANO a 44% reduction,3 and HPTN 052 a significant decrease in adverse clinical events and a 96% reduction in HIV transmission.